Видео ютуба по тегу Belamaf

Optimizing the dose of belamaf in transplant-ineligible NDMM: insights from the DREAMM-9 trial
Optimizing the dose of belamaf in transplant-ineligible NDMM: insights from the DREAMM-9 trial
What you need to know about keratopathy management with belamaf
What you need to know about keratopathy management with belamaf
Белантамаб Мафодотин при множественной миеломе | НЭМ
Белантамаб Мафодотин при множественной миеломе | НЭМ
Phase 3, open-label, randomized trial comparing belamaf to Pd in RRMM: DREAMM-3 study
Phase 3, open-label, randomized trial comparing belamaf to Pd in RRMM: DREAMM-3 study
Belamaf monotherapy induced rapid responses without unexpected toxicity in R/R AL amyloidosis
Belamaf monotherapy induced rapid responses without unexpected toxicity in R/R AL amyloidosis
DREAMM-5: belamaf therapy in R/R myeloma
DREAMM-5: belamaf therapy in R/R myeloma
DREAMM-6: belamaf-based combination therapy in R/R MM
DREAMM-6: belamaf-based combination therapy in R/R MM
Mechanism of action of belantamab mafodotin
Mechanism of action of belantamab mafodotin
DREAMM-7: Belamaf+BVd vs DVd in RRMM, analyses of phase 3 trial comparing regimens after relapse
DREAMM-7: Belamaf+BVd vs DVd in RRMM, analyses of phase 3 trial comparing regimens after relapse
BelaRd trial: belamaf, lenalidomide, and dex in newly diagnosed MM
BelaRd trial: belamaf, lenalidomide, and dex in newly diagnosed MM
Deciphering the association between ocular AEs and the clinical activity of belamaf in myeloma
Deciphering the association between ocular AEs and the clinical activity of belamaf in myeloma
The clinical journey of belantamab mafodotin for myeloma and lessons learned in its development
The clinical journey of belantamab mafodotin for myeloma and lessons learned in its development
Updated results from DREAMM-8: belamaf plus pomalidomide and dexamethasone in R/R myeloma
Updated results from DREAMM-8: belamaf plus pomalidomide and dexamethasone in R/R myeloma
DREAMM-5 sub-study: belamaf in combination with feladilimab in the treatment of R/R myeloma
DREAMM-5 sub-study: belamaf in combination with feladilimab in the treatment of R/R myeloma
DREAMM-6: Belamaf with BorDex for R/R myeloma
DREAMM-6: Belamaf with BorDex for R/R myeloma
Long-term outcomes from the BelaRd trial and the evaluation of a VRA tool to guide belamaf dosing
Long-term outcomes from the BelaRd trial and the evaluation of a VRA tool to guide belamaf dosing
Real-world ocular monitoring and safety of belantamab mafodotin monotherapy in RRMM
Real-world ocular monitoring and safety of belantamab mafodotin monotherapy in RRMM
Belantamab Mafodotin (Blenrep) - A BCMA -Directed Antibody Drug Conjugate for Multiple Myeloma
Belantamab Mafodotin (Blenrep) - A BCMA -Directed Antibody Drug Conjugate for Multiple Myeloma
Dr. Lonial on the FDA Approval of Belantamab Mafodotin in Multiple Myeloma
Dr. Lonial on the FDA Approval of Belantamab Mafodotin in Multiple Myeloma
Knowing Your Myeloma Therapy: BLENREP
Knowing Your Myeloma Therapy: BLENREP